• Dragana Gabrić, Vlaho Brailo, Aleksandra Ivek, Karla Krpan, Nena Matulić, Danko Velimir Vrdoljak, Anja Baraba, and Vanja Vučićević Boras.
• 1Department of Oral Surgery, School of Dental Medicine, University of Zagreb, Zagreb, Croatia; 2Department of Oral Medicine, School of Dental Medicine, University of Zagreb, Zagreb University Hospital Centre, Zagreb, Croatia; 3student, School of Dental Medicine, University of Zagreb, Zagreb, Croatia; 4PhD student, School of Dental Medicine, University of Zagreb, Zagreb, Croatia; 5University Hospital for Tumors, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia; 6Department of Endodontics and Restorative Dentistry, School of Dental Medicine, University of Zagreb, Zagreb, Croatia.
• Acta Clin Croat. 2019 Dec 1; 58 (4): 615620615-620.

AbstractThe use of lasers for treatment of oral leukoplakia has gained a lot of interest in the past years, however, data on the use of Er:YAG laser are scarce. The aim of this study was to compare the efficacy of Er:YAG laser and 1% topical isotretinoin in the treatment of 27 oral leukoplakia patients. Er:YAG laser (LightWalker AT, Fotona, Slovenia) was used in 27 patients with 27 leukoplakia lesions. Postoperative pain was assessed by use of visual analog scale (VAS), and the impact of laser treatment on the quality of life was assessed by the OHIP-14 questionnaire (Croatian version). Control group consisted of the same 27 patients previously treated with 1% topical isotretionin three times a day during the period of one year. No improvement in the size of leukoplakia lesions was observed after treatment with topical isotretinoin. There were significant differences between men and women according to leukoplakia localization, number of laser sessions and VAS (p<0.05). At follow-up after six months and one year, there was no recurrence of lesions. Er:YAG laser is a successful treatment for oral leukoplakia. Topical isotretionin treatment is unsuccessful in patients with oral leukoplakia.

21 keywords...

hide…